|
PRTFDC1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.23659999998294E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.51990000002633E-06 |
| Normal-vs-Stage2 |
5.832000E-01 |
| Normal-vs-Stage3 |
3.68200000000485E-05 |
| Normal-vs-Stage4 |
1.883630E-02 |
| Stage1-vs-Stage2 |
2.424400E-02 |
| Stage1-vs-Stage3 |
4.331400E-01 |
| Stage1-vs-Stage4 |
9.740000E-01 |
| Stage2-vs-Stage3 |
1.910030E-02 |
| Stage2-vs-Stage4 |
1.466590E-01 |
| Stage3-vs-Stage4 |
6.114000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.20380000412368E-08 |
| Normal-vs-AfricanAmerican |
9.981200E-01 |
| Normal-vs-Asian |
1.704160E-01 |
| Caucasian-vs-AfricanAmerican |
1.075800E-01 |
| Caucasian-vs-Asian |
2.901500E-02 |
| AfricanAmerican-vs-Asian |
5.186800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.183500E-02 |
| Normal-vs-Female |
3.66249999994572E-07 |
| Male-vs-Female |
1.655630E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.77649999999874E-05 |
| Normal-vs-Age(41-60Yrs) |
7.20720000013664E-07 |
| Normal-vs-Age(61-80Yrs) |
1.003980E-01 |
| Normal-vs-Age(81-100Yrs) |
1.004980E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.820600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.575000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.977780E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.837700E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.063000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.022000E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.42489999999762E-05 |
| Classical-VS-Follicular |
1.89064999999156E-05 |
| Classical-VS-Other |
4.226600E-01 |
| Classical-VS-Normal |
4.27559999627292E-08 |
| Tall-VS-Follicular |
4.34840052854213E-10 |
| Tall-VS-Other |
5.797800E-02 |
| Tall-VS-Normal |
1.85407245112401E-14 |
| Follicular-VS-Other |
4.014000E-01 |
| Follicular-VS-Normal |
4.186400E-01 |
| Other-VS-Normal |
2.275200E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.977900E-04 |
| Normal-vs-N1 |
2.398600E-03 |
| N0-vs-N1 |
3.871600E-01 |
|
|
